These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37494827)

  • 1. The path to hepatitis C elimination: who are we leaving behind and why?
    Rockstroh JK; Swan T; Chang J; Elamouri F; Lloyd AR
    J Int AIDS Soc; 2023 Jul; 26(7):e26136. PubMed ID: 37494827
    [No Abstract]   [Full Text] [Related]  

  • 2. A National Hepatitis C Elimination Program in the United States: A Historic Opportunity.
    Fleurence RL; Collins FS
    JAMA; 2023 Apr; 329(15):1251-1252. PubMed ID: 36892976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Elimination of hepatitis C virus in Denmark].
    Døssing A; Røge BT; Madsen LG; Laursen AL; Hansen JB; Bukh J; Weis N
    Ugeskr Laeger; 2020 Feb; 182(9):. PubMed ID: 32138816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.
    Clement ME; Collins LF; Wilder JM; Mugavero M; Barker T; Naggie S
    Infect Dis Clin North Am; 2018 Jun; 32(2):407-423. PubMed ID: 29778263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of HCV in Russia: Barriers and Perspective.
    Isakov V; Nikityuk D
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
    Jonas MC; Loftus B; Horberg MA
    Infect Dis Clin North Am; 2018 Jun; 32(2):481-493. PubMed ID: 29778267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
    van Dijk M; Drenth JPH;
    J Viral Hepat; 2020 Dec; 27(12):1270-1283. PubMed ID: 32964615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategy for the Elimination of Hepatitis C in Cantabria.
    Crespo J; Tejerina Puente A; Cuadrado A; Llerena S; Cabezas J;
    Rev Esp Enferm Dig; 2020 Jul; 112(7):565-570. PubMed ID: 32543873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals-Data from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Lutz T; Cordes C; Klausen G; Scholten S; Hillenbrand H; Cornberg M; Baumgarten A; Rockstroh JK;
    J Viral Hepat; 2021 Nov; 28(11):1660-1664. PubMed ID: 34289197
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C virus screening to reveal a better picture of infection.
    Medici MC; Galli C; Calderaro A
    Trends Microbiol; 2015 Jun; 23(6):324-6. PubMed ID: 26047087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action.
    Gupta N; Kateera F; Desalegn H; Ocama P; Njouom R; Lacombe K
    J Hepatol; 2020 Mar; 72(3):583-584. PubMed ID: 31836263
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C virus: current concepts and future challenges.
    Klenerman P; Gupta PK
    QJM; 2012 Jan; 105(1):29-32. PubMed ID: 22123990
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study.
    McLeod A; Hutchinson SJ; Smith S; Leen C; Clifford S; McAuley A; Wallace LA; Barclay ST; Bramley P; Dillon JF; Fraser A; Gunson RN; Hayes PC; Kennedy N; Peters E; Templeton K; Goldberg DJ
    HIV Med; 2021 May; 22(5):334-345. PubMed ID: 33350049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards curative therapy of chronic viral hepatitis.
    Bartenschlager R; Urban S; Protzer U
    Z Gastroenterol; 2019 Jan; 57(1):61-73. PubMed ID: 30641605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach.
    Cachay ER; Mena A; Morano L; Benitez L; Maida I; Mendoza C; Hill L; Torriani F; Soriano V; Mathews WC;
    J Int Assoc Provid AIDS Care; 2021; 20():23259582211024771. PubMed ID: 34132142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why co-infection may no longer be 'special'.
    Highleyman L
    Posit Aware; 2017; 29(1):28-9. PubMed ID: 29505206
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards HCV extinction with modern HCV treatment? "Yes we can!".
    Torti C; Focà A; Carosi G
    BMC Infect Dis; 2012; 12 Suppl 2(Suppl 2):S1. PubMed ID: 23174030
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
    Lucidarme D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B112-20. PubMed ID: 12180278
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-Positive Recipients in the Direct-Acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Goldfarb DA
    J Urol; 2020 Dec; 204(6):1369. PubMed ID: 32955983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.